Perspective Therapeutics Price Target Cut to $27.00/Share From $29.00 by RBC Capital
Perspective Therapeutics Analyst Ratings
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $27
RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)
Buy Rating Justified by Perspective Therapeutics's Promising Clinical Data and Strategic Expansion
JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $17
Perspective Therapeutics Analyst Ratings
Oppenheimer Keeps Their Buy Rating on Perspective Therapeutics (CATX)
Buy Rating on Perspective Therapeutics: Advancing Clinical Programs and Strong Financials Promise Value Creation
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $29
Perspective Therapeutics Analyst Ratings
B of A Securities Initiates Coverage On Perspective Therapeutics With Buy Rating, Announces Price Target of $24
BofA Securities Initiates Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $24
Buy Rating Affirmed for Perspective Therapeutics Amid Promising Radiopharmaceutical Advances
Perspective Therapeutics Analyst Ratings
Perspective Therapeutics Analyst Ratings
Perspective Therapeutics Analyst Ratings
RBC Capital Reiterates Outperform on Perspective Therapeutics, Maintains $3 Price Target
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Perspective Therapeutics (CATX) and Glaukos (GKOS)
No Data